|
1
|
López-Hernández Y, Oropeza-Valdez JJ, Blanco-Sandate JO, Herrera-Van Oostdam AS, Zheng J, Chi Guo A, Lima-Rogel V, Rajabzadeh R, Salgado-Bustamante M, Adrian-Lopez J, Castillo CG, Robles Arguelles E, Monárrez-Espino J, Mandal R, Wishart DS. The Urinary Metabolome of Healthy Newborns. Metabolites 2020; 10:E165. [PMID: 32340350 PMCID: PMC7240964 DOI: 10.3390/metabo10040165] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Revised: 04/18/2020] [Accepted: 04/21/2020] [Indexed: 02/06/2023] Open
Abstract
The knowledge of normal metabolite values for neonates is key to establishing robust cut-off values to diagnose diseases, to predict the occurrence of new diseases, to monitor a neonate's metabolism, or to assess their general health status. For full term-newborns, many reference biochemical values are available for blood, serum, plasma and cerebrospinal fluid. However, there is a surprising lack of information about normal urine concentration values for a large number of important metabolites in neonates. In the present work, we used targeted tandem mass spectrometry (MS/MS)-based metabolomic assays to identify and quantify 136 metabolites of biomedical interest in the urine from 48 healthy, full-term term neonates, collected in the first 24 h of life. In addition to this experimental study, we performed a literature review (covering the past eight years and over 500 papers) to update the references values in the Human Metabolome Database/Urine Metabolome Database (HMDB/UMDB). Notably, 86 of the experimentally measured urinary metabolites are being reported in neonates/infants for the first time and another 20 metabolites are being reported in human urine for the first time ever. Sex differences were found for 15 metabolites. The literature review allowed us to identify another 78 urinary metabolites with concentration data. As a result, reference concentration values and ranges for 378 neonatal urinary metabolites are now publicly accessible via the HMDB.
Collapse
Affiliation(s)
- Yamilé López-Hernández
- CONACyT, Metabolomics and Proteomics Laboratory, Universidad Autónoma de Zacatecas, Zacatecas 98000, Mexico
| | - Juan José Oropeza-Valdez
- Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico;
| | - Jorge O. Blanco-Sandate
- CIACYT-Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico; (J.O.B.-S.); (C.G.C.)
| | - Ana Sofia Herrera-Van Oostdam
- Biochemistry Department, Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico; (A.S.H.-V.O.); (M.S.-B.)
| | - Jiamin Zheng
- The Metabolomics Innovation Center, University of Alberta, Edmonton, AB T6G1C9, Canada; (J.Z.); (A.C.G.); (R.R.); (R.M.)
| | - An Chi Guo
- The Metabolomics Innovation Center, University of Alberta, Edmonton, AB T6G1C9, Canada; (J.Z.); (A.C.G.); (R.R.); (R.M.)
| | - Victoria Lima-Rogel
- Hospital Central “Dr. Ignacio Morones Prieto”, San Luis Potosí 78290, Mexico;
| | - Rahmatollah Rajabzadeh
- The Metabolomics Innovation Center, University of Alberta, Edmonton, AB T6G1C9, Canada; (J.Z.); (A.C.G.); (R.R.); (R.M.)
| | - Mariana Salgado-Bustamante
- Biochemistry Department, Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico; (A.S.H.-V.O.); (M.S.-B.)
| | - Jesus Adrian-Lopez
- MicroRNAs Laboratory, Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas, Zacatecas 98000, Mexico; (J.A.-L.); (E.R.A.)
| | - C. G. Castillo
- CIACYT-Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico; (J.O.B.-S.); (C.G.C.)
| | - Emilia Robles Arguelles
- MicroRNAs Laboratory, Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas, Zacatecas 98000, Mexico; (J.A.-L.); (E.R.A.)
| | | | - Rupasri Mandal
- The Metabolomics Innovation Center, University of Alberta, Edmonton, AB T6G1C9, Canada; (J.Z.); (A.C.G.); (R.R.); (R.M.)
| | - David S. Wishart
- The Metabolomics Innovation Center, University of Alberta, Edmonton, AB T6G1C9, Canada; (J.Z.); (A.C.G.); (R.R.); (R.M.)
| |
Collapse
|
|
2
|
LC–MS/MS analysis of the central energy and carbon metabolites in biological samples following derivatization by dimethylaminophenacyl bromide. J Chromatogr A 2019; 1608:460413. [DOI: 10.1016/j.chroma.2019.460413] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 07/27/2019] [Accepted: 07/30/2019] [Indexed: 12/12/2022]
|
|
3
|
Renoprotective effect and mechanism of polysaccharide from Polyporus umbellatus sclerotia on renal fibrosis. Carbohydr Polym 2019; 212:1-10. [PMID: 30832835 DOI: 10.1016/j.carbpol.2019.02.026] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 01/25/2019] [Accepted: 02/08/2019] [Indexed: 01/02/2023]
Abstract
As a fungal polysaccharide, polysaccharide (PPUS) from Polyporus umbellatus sclerotia have showed remarkable anti-inflammatory activities. In view of the closely relationship between inflammation and renal fibrosis, and considering the significant role of other fungal polysaccharides on treatment of renal fibrosis, we speculated that PPUS may have therapeutic effects on renal fibrosis. However, there was not any reports about PPUS treatment this disease. The purpose of this paper is to investigate renoprotective effect and mechanism of PPUS on renal fibrosis. The results indicated that PPUS can improve renal function and ameliorate the degree of renal collagen deposition and further fibrosis. Its mechanism was found to be related with decreased inflammation, suppressive epithelial-mesenchymal transition, reconstructed the balance of matrix metalloproteinases and tissue inhibitor of metalloproteinases, and pro-fibrotic and anti-fibrotic factors. The data implied that PPUS can serve as a clinical candidate on treatment of renal interstitial fibrosis.
Collapse
|
|
4
|
Abstract
Children interact with the physical environment differently than adults, and are uniquely susceptible to environmental toxicants. Routes of absorption, distribution, metabolism, and target organ toxicities vary as children grow and develop. This article summarizes the sources of exposure and known adverse effects of toxicants that are ubiquitous in our environment, including tobacco smoke, ethanol, solvents, heavy metals, volatile organic compounds, persistent organic pollutants, and pesticides. Preventive strategies that may be used in counseling children and their families are highlighted.
Collapse
|